Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Mar;84(5):643–650. doi: 10.1054/bjoc.2000.1649

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer

H Kim 1,2, A Scorilas 1,2, D Katsaros 3, G M Yousef 1,2, M Massobrio 3, S Fracchioli 3, R Piccinno 3, G Gordini 4, E P Diamandis 1,2
PMCID: PMC2363783  PMID: 11237385

Abstract

Kallikrein gene 5 (KLK5, also known as KLK-L2), located on chromosome 19q13.4, is one of the newly identified members of the kallikrein gene family, which is a subgroup of the serine protease enzyme family. In normal human tissues, KLK5 is highly expressed in skin, mammary gland and testis. Preliminary RT-PCR analysis has indicated that KLK5 is expressed in a subset of ovarian tumours. We have thus hypothesized that KLK5 may be a new prognostic indicator in ovarian cancer. We have examined the mRNA expression of KLK5 in 142 malignant ovarian tissues. Tumours were pulverized, total RNA was extracted, and cDNA was prepared by reverse transcription. KLK5 was amplified by PCR using gene specific primers, and the identity of the PCR product was verified by sequencing. Ovarian tissues were then classified as KLK5 positive or negative, based on ethidium bromide staining of the PCR product on agarose gels. KLK5 was found to be highly expressed in 58/142 (41%) of ovarian cancer samples while its level of expression was very low in normal ovarian tissues. We found a strong positive relation between KLK5 expression and tumour grade (P = 0.006) and disease stage (P = 0.027). Univariate survival analysis revealed that patients with ovarian tumours positive for KLK5 expression had an increased risk for relapse and death (P = 0.018 and 0.022, respectively). In multivariate analysis, KLK5 expression showed independent prognostic value only in the subset of tumours with lower grade disease (grades I and II). We conclude that KLK5 expression is associated with more aggressive forms of epithelial ovarian carcinoma and has indepdent prognostic value in low grade tumours. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: kallikrein gene 5, ovarian carcinoma, gene expression, survival analysis, prognostic markers, human kallikreins

Full Text

The Full Text of this article is available as a PDF (91.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anisowicz A., Sotiropoulou G., Stenman G., Mok S. C., Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med. 1996 Sep;2(5):624–636. [PMC free article] [PubMed] [Google Scholar]
  2. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994 Jan-Feb;44(1):7–26. doi: 10.3322/canjclin.44.1.7. [DOI] [PubMed] [Google Scholar]
  3. Day T. G., Jr, Gallager H. S., Rutledge F. N. Epithelial carcinoma of the ovary:prognostic importance of histologic grade. Natl Cancer Inst Monogr. 1975 Oct;42:15–21. [PubMed] [Google Scholar]
  4. Diamandis E. P., Yousef G. M., Luo L. Y., Magklara A., Obiezu C. V. The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab. 2000 Mar;11(2):54–60. doi: 10.1016/s1043-2760(99)00225-8. [DOI] [PubMed] [Google Scholar]
  5. Duffy M. J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992 May;10(3):145–155. doi: 10.1007/BF00132746. [DOI] [PubMed] [Google Scholar]
  6. Hanahan D., Weinberg R. A. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57–70. doi: 10.1016/s0092-8674(00)81683-9. [DOI] [PubMed] [Google Scholar]
  7. Herszènyi L., Plebani M., Carraro P., De Paoli M., Roveroni G., Cardin R., Tulassay Z., Naccarato R., Farinati F. The role of cysteine and serine proteases in colorectal carcinoma. Cancer. 1999 Oct 1;86(7):1135–1142. doi: 10.1002/(sici)1097-0142(19991001)86:7<1135::aid-cncr6>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  8. Herszényi L., Plebani M., Carraro P., De Paoli M., Roveroni G., Cardin R., Foschia F., Tulassay Z., Naccarato R., Farinati F. Proteases in gastrointestinal neoplastic diseases. Clin Chim Acta. 2000 Feb 15;291(2):171–187. doi: 10.1016/s0009-8981(99)00227-2. [DOI] [PubMed] [Google Scholar]
  9. Kristensen G. B., Tropé C. Epithelial ovarian carcinoma. Lancet. 1997 Jan 11;349(9045):113–117. doi: 10.1016/S0140-6736(96)06071-0. [DOI] [PubMed] [Google Scholar]
  10. Kuhn W., Schmalfeldt B., Reuning U., Pache L., Berger U., Ulm K., Harbeck N., Späthe K., Dettmar P., Höfler H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999 Apr;79(11-12):1746–1751. doi: 10.1038/sj.bjc.6690278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991 Jan 25;64(2):327–336. doi: 10.1016/0092-8674(91)90642-c. [DOI] [PubMed] [Google Scholar]
  12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  13. Monsky W. L., Kelly T., Lin C. Y., Yeh Y., Stetler-Stevenson W. G., Mueller S. C., Chen W. T. Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res. 1993 Jul 1;53(13):3159–3164. [PubMed] [Google Scholar]
  14. Powell W. C., Knox J. D., Navre M., Grogan T. M., Kittelson J., Nagle R. B., Bowden G. T. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res. 1993 Jan 15;53(2):417–422. [PubMed] [Google Scholar]
  15. Pujol P., Rey J. M., Nirde P., Roger P., Gastaldi M., Laffargue F., Rochefort H., Maudelonde T. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res. 1998 Dec 1;58(23):5367–5373. [PubMed] [Google Scholar]
  16. Tanimoto H., Underwood L. J., Shigemasa K., Yan Yan M. S., Clarke J., Parmley T. H., O'Brien T. J. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer. 1999 Nov 15;86(10):2074–2082. [PubMed] [Google Scholar]
  17. Tryggvason K., Höyhtyä M., Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987 Nov 25;907(3):191–217. doi: 10.1016/0304-419x(87)90006-0. [DOI] [PubMed] [Google Scholar]
  18. Yousef G. M., Diamandis E. P. The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem. 1999 Dec 31;274(53):37511–37516. doi: 10.1074/jbc.274.53.37511. [DOI] [PubMed] [Google Scholar]
  19. Yousef G. M., Luo L. Y., Diamandis E. P. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. 1999 Jul-Aug;19(4B):2843–2852. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES